22157.jpg
Worldwide Irritable Bowel Syndrome Treatment Industry to 2028 - Increasing Disposable Incomes Presents Opportunities
July 12, 2021 05:23 ET | Research and Markets
Dublin, July 12, 2021 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Type [IBS with Diarrhea, IBS with Constipation, and...
22157.jpg
Worldwide Irritable Bowel Syndrome with Constipation Drugs Industry to 2028 - Rising Prevalence of Gastrointestinal Disorders Will Significantly Increase the Demand
February 26, 2021 06:18 ET | Research and Markets
Dublin, Feb. 26, 2021 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome with Constipation Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players,...
22157.jpg
Insights on the Opiod Induced Constipation Drugs Global Market to 2028 - by Drug Type, Prescription Type and Geography
February 22, 2021 07:18 ET | Research and Markets
Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Opiod Induced Constipation Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies...
China Food and Drug Administration Accepts IND for Pivotal Study of AMITIZA(R) (lubiprostone)
June 15, 2015 16:02 ET | Sucampo Pharmaceuticals Inc
BETHESDA, Md., June 15, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the China Food and Drug Administration...
Sucampo Announces Acceptance of New Drug Submission for AMITIZA(R) (lubiprostone) by Health Canada
December 30, 2014 17:00 ET | Sucampo Pharmaceuticals Inc
BETHESDA, Md., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Health Canada has accepted the...
Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone)
October 21, 2014 18:00 ET | Sucampo Pharmaceuticals Inc
BETHESDA, Md., October 21, 2014 and OSAKA, Japan, October 22, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, and Takeda...
Sucampo Announces Extension of AMITIZA(R) (lubiprostone) License and Collaboration Agreement With Takeda
October 14, 2014 06:45 ET | Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it signed on October 9, 2014 an...
Clinical Data for AMITIZA(R) Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting
October 13, 2014 06:45 ET | Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 13, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for AMITIZA®...
Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA(R) (lubiprostone) for Chronic Idiopathic Constipation
September 29, 2014 06:45 ET | Sucampo Pharmaceuticals Inc
BETHESDA, Md., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) and its development and commercialization partner, Takeda Pharmaceuticals (Takeda), today...
Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone
August 21, 2014 16:30 ET | Sucampo Pharmaceuticals Inc
BETHESDA, Md., Aug. 21, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that its subsidiary, Sucampo AG, has signed...